| P2093 | author name string | John J Haddad | |
| P2860 | cites work | Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation | Q22004269 |
| | Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor | Q24321564 |
| | Fibroblast growth factors | Q24542507 |
| | pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions | Q24561464 |
| | Self-assembled DNA nanostructures for distance-dependent multivalent ligand-protein binding | Q24642639 |
| | Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors | Q24644787 |
| | A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points | Q24651047 |
| | Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: a possible role for protein tyrosine kinase | Q24672837 |
| | The protein kinase family: conserved features and deduced phylogeny of the catalytic domains | Q27860528 |
| | Protein modules and signalling networks | Q27860694 |
| | Emerging issues in receptor protein tyrosine phosphatase function: lifting fog or simply shifting? | Q28138232 |
| | The protein tyrosine kinase family of the human genome | Q28140214 |
| | [Angiogenesis and anti-angiogenesis in human neoplasms. Recent developments and the therapeutic prospects] | Q73866092 |
| | [Tumor angiogenesis inhibitors: media and scientific aspects] | Q77395375 |
| | Structure-based design and synthesis of small molecule protein-tyrosine phosphatase 1B inhibitors | Q77634522 |
| | Erratum [McMahon G, Sun L, Liang C, Tang C: Protein kinase inhibitors: structural determinants for target specificity. Current Opin Drug Discovery Dev (1998) 1(2):131-146. Correction to the structure of Compound 74 (SU-5874) in Figure 9] | Q84337647 |
| | The GDNF family ligands and receptors - implications for neural development | Q28144957 |
| | Receptor tyrosine kinase signalling as a target for cancer intervention strategies | Q28188287 |
| | GDNF family neurotrophic factor signaling: four masters, one servant? | Q28198154 |
| | The splice variants of vascular endothelial growth factor (VEGF) and their receptors | Q28200155 |
| | Identification of a new fibroblast growth factor receptor, FGFR5 | Q28202842 |
| | N-glycosylation of fibroblast growth factor receptor 1 regulates ligand and heparan sulfate co-receptor binding | Q28250986 |
| | RET tyrosine kinase signaling in development and cancer | Q28258597 |
| | Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis | Q28269738 |
| | Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 |
| | Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET | Q28284037 |
| | Receptors for fibroblast growth factors | Q28285082 |
| | A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma | Q28294793 |
| | Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer | Q28306292 |
| | Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases | Q28377765 |
| | Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium | Q28512027 |
| | Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium | Q28587604 |
| | Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice | Q28593600 |
| | A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF | Q28646512 |
| | Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 |
| | Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 |
| | Vascular endothelial growth factor (VEGF) and its receptors | Q29615390 |
| | New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. | Q31402601 |
| | Angiogenesis: regulators and clinical applications | Q31923131 |
| | Regulation of receptor tyrosine kinase signaling by endocytic trafficking | Q32029952 |
| | The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts | Q32061790 |
| | Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia | Q33377623 |
| | Strategies toward the design of novel and selective protein tyrosine kinase inhibitors | Q33716108 |
| | The structure-based design of ATP-site directed protein kinase inhibitors | Q33737650 |
| | Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation | Q33815989 |
| | Update on the pathogenesis and treatment of Kaposi sarcoma | Q33883271 |
| | VEGF receptor signaling in tumor angiogenesis | Q33914422 |
| | The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma | Q33914429 |
| | Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor | Q33941495 |
| | Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent | Q33963448 |
| | Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors | Q33967714 |
| | Anti-angiogenic agents: clinical trial design and therapies in development | Q34013828 |
| | Angiogenesis inhibitors. New agents in cancer therapy | Q34087227 |
| | Antiangiogenesis -- therapeutic strategies and clinical implications for brain tumors | Q34178886 |
| | Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 |
| | Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders | Q34292807 |
| | Role of protein tyrosine kinase inhibitors in cancer therapeutics. | Q34294537 |
| | Molecular targets and cancer therapeutics: discovery, development and clinical validation | Q34332769 |
| | Association of Lyn tyrosine kinase with the nuclear matrix and cell-cycle-dependent changes in matrix-associated tyrosine kinase activity | Q34376815 |
| | Flk-1 as a target for tumor growth inhibition. | Q34392604 |
| | Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors | Q34436684 |
| | Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications | Q34508708 |
| | Receptor tyrosine kinase inhibitors. | Q34510074 |
| | Angiogenesis inhibitors in oncology. The research continues | Q34566037 |
| | Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy | Q34719233 |
| | Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. | Q34743609 |
| | Receptor tyrosine kinase signaling: a view from quantitative proteomics | Q35003116 |
| | Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy | Q35013457 |
| | Redox and oxidant-mediated regulation of apoptosis signaling pathways: immuno-pharmaco-redox conception of oxidative siege versus cell death commitment | Q35751816 |
| | Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials | Q36181201 |
| | Regulators of Angiogenesis | Q36653534 |
| | Recent advances in protein kinase inhibition: current molecular scaffolds used for inhibitor synthesis | Q37570148 |
| | Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells | Q40809633 |
| | Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases | Q40868657 |
| | Gene therapy of malignant glioma via inhibition of tumor angiogenesis | Q41140305 |
| | Angiogenesis in ischemic heart disease | Q41338703 |
| | Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant | Q41488146 |
| | Protein kinases and phosphatases are involved in erythropoietin-mediated signal transduction | Q41627771 |
| | Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases | Q42541293 |
| | SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types | Q42820704 |
| | The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function | Q42832614 |
| | Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. | Q43540254 |
| | Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis | Q46273746 |
| | Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). | Q46625520 |
| | Are angiostatin and endostatin cures for cancer? | Q47992021 |
| | Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme | Q49168241 |
| | Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications. | Q55475689 |
| | High throughput assay for inhibitors of the epidermal growth factor receptor-associated tyrosine kinase | Q70511353 |
| | [Development of anti tumor agents targeting angiogenesis] | Q73066845 |
| | Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor | Q73674093 |
| P433 | issue | 2 | |
| P921 | main subject | angiogenesis | Q539568 |
| | romiplostim | Q1235195 |
| P304 | page(s) | 103-123 | |
| P577 | publication date | 2011-09-23 | |
| P1433 | published in | Saudi Pharmaceutical Journal | Q15763912 |
| P1476 | title | The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties | |
| P478 | volume | 20 | |